Atlanpole Biotherapies also supported the IGO labex and, to strengthen industrial relationships during the project, was appointed to give assistance in emerging innovations.

Atlanpole Biotherapies is one of the seven competitiveness cluster dedicated to health, accredited by the French government in 2005. It gathers 80 companies, 5 Universities (with 51 research units), 2 Hospital Universities and 1 veterinary school. Its mission is to boost innovation mainly through public/private partnerships and international networking.

Immunobiotherapies is one of the 3 strategic R&D axis of Atlanpole Biotherapies Cluster. Thus a regional complete value chain is functional to support the innovation efforts in transplantation and oncology, from basic research to GMP biomanufacturing. This value chain is designed to support the development of any Immunotherapies such as cancer vaccines, antibodies, immuno cytokines, radiolabelled antibodies, nanofitines, immunomodulators etc…Key core facilities include immunomonitoring for preclinal and clinical phases or big animal experimentation (surgery, imaging…).

Atlanpole Biotherapies, represented by Mrs Duisit (, is member of the IGO Labex directory board and is your contact for any inquiries about industrial collaboration setting up.